{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:21:46Z","timestamp":1791134506604,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1993,11,1]],"date-time":"1993-11-01T00:00:00Z","timestamp":752112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1993,11]]},"DOI":"10.1007\/bf02244337","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T17:53:50Z","timestamp":1131990830000},"page":"76-82","source":"Crossref","is-referenced-by-count":93,"title":["Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers"],"prefix":"10.1007","volume":"113","author":[{"given":"Emmanuel","family":"Mignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Arrigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Guilleminault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02244337_CR1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1212\/WNL.42.2.410","volume":"42","author":"M Aldrich","year":"1992","unstructured":"Aldrich M(1992) Narcolepsy. Neurology 42:34\u201343","journal-title":"Neurology"},{"key":"BF02244337_CR2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0014-2999(89)90363-4","volume":"166","author":"PH Andersen","year":"1989","unstructured":"Andersen PH (1989) The dopamine uptake inhibitor. GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493\u2013504","journal-title":"Eur J Pharmacol"},{"key":"BF02244337_CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/syn.890060105","volume":"6","author":"NM Appel","year":"1990","unstructured":"Appel NM, Mitchell WMM, Contrera JF, De Souza EB (1990) Effects of high dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse 6:33\u201344","journal-title":"Synapse"},{"key":"BF02244337_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0091-3057(76)90298-7","volume":"5","author":"DA Babcock","year":"1976","unstructured":"Babcock DA, Narver EL, Dement WC, Mitler MM (1976) Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 5:599\u2013602.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02244337_CR5","first-page":"199","volume-title":"Brain mechanisms of sleep","author":"T Baker","year":"1985","unstructured":"Baker T, Dement WC (1985) Canine narcolepsy-cataplexy syndrome; evidence for an inherited monoaminergic-cholinergic imbalance. In: DJ McGinty, Drucker-Collin R, Morrison A, Parmeggiani P (eds) Brain mechanisms of sleep. Raven, New York, pp 199\u2013233"},{"key":"BF02244337_CR6","first-page":"483","volume":"18","author":"L Bertilsson","year":"1980","unstructured":"Bertilsson L, Tuck JR, Siwers B (1980) Biochemical effects of Zimelidine in man. Eur J Pharmacol 18:483\u2013487","journal-title":"Eur J Pharmacol"},{"key":"BF02244337_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-197918010-00001","volume":"18","author":"RN Brogden","year":"1979","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS (1979) Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18:1\u201324","journal-title":"Drugs"},{"key":"BF02244337_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00428820","volume":"42","author":"J Buus Lassen","year":"1975","unstructured":"Buus Lassen J, Squires F, Christensen JA, Molander L (1975) Neurochemical and pharmacological studies on a new 5-HT uptake inhibitor, FG 4963, with potential antidepressant properties. Psychopharmacology 42:21\u201326","journal-title":"Psychopharmacology"},{"key":"BF02244337_CR9","first-page":"605","volume-title":"Narcolepsy","author":"J Cadilhac","year":"1976","unstructured":"Cadilhac J (1976) Tricyclic and REM sleep. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum, New York, pp 605\u2013623"},{"key":"BF02244337_CR10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF00427436","volume":"83","author":"G Chouinard","year":"1984","unstructured":"Chouinard G, Annabel L, Bradwejn J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126\u2013128","journal-title":"Psychopharmacology"},{"issue":"11","key":"BF02244337_CR11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0028-3908(83)90198-3","volume":"22","author":"RM Ferris","year":"1983","unstructured":"Ferris RM, Beaman OJ (1983) Bupropion; a new antidepressant drug, the mechanism of action of which is not associated with down regulation of postsynaptic beta-adrenergic, serotoninergic (5-HT2), alpha-2 adrenergic, imipramine and dopaminergic receptors in the brain. Neuropharmacology 22[11] 1257\u20131983","journal-title":"Neuropharmacology"},{"issue":"5","key":"BF02244337_CR12","first-page":"455","volume":"1","author":"RW Fuller","year":"1975","unstructured":"Fuller RW, Snoddy HD, Molloy BB (1975) Blockade of amine depletion by nisoxetine in comparison to other uptake inhibitors. Psychopharmacol Commun 1[5]:455\u2013464","journal-title":"Psychopharmacol Commun"},{"key":"BF02244337_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00609869","volume":"15","author":"JM Gaillard","year":"1979","unstructured":"Gaillard JM, Kafi S (1979) Involvement of pre- and postsynaptic receptors in catecholaminergic control of paradoxical sleep in man. Eur J Clin Pharmacol 15:83\u201389","journal-title":"Eur J Clin Pharmacol"},{"key":"BF02244337_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0074-7742(08)60089-6","volume":"29","author":"S Garattini","year":"1988","unstructured":"Garattini S, Mennini T (1988) Critical notes on the specificity of drugs in the study of metabolism and functions of brain monoamines. Inter Rev Neurobiol 29:259\u2013280","journal-title":"Inter Rev Neurobiol"},{"issue":"Suppl 2","key":"BF02244337_CR15","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002826-198912002-00003","volume":"12","author":"S Garattini","year":"1989","unstructured":"Garattini S, Mennini T (1989) Pharmacology of amineptine: synthesis and update. Clin. Neuropharmacol (Suppl 2) 12:S13-S18","journal-title":"Clin. Neuropharmacol"},{"key":"BF02244337_CR16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/2041318a0","volume":"204","author":"J Glowinski","year":"1964","unstructured":"Glowinski J, Axelrod J (1964) Inhibition of uptake of tritiated noradrenaline in intact brain by imipramine and structurally related compounds. Nature, 204:1318\u20131320","journal-title":"Nature"},{"issue":"1","key":"BF02244337_CR17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/sleep\/9.1.275","volume":"9","author":"C Guilleminault","year":"1986","unstructured":"Guilleminault C, Mancuso J, Quera Salva MA, Hayes B, Mitler M, Poirier G. Montplaisir J (1986) Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 9 [1] 275\u2013279","journal-title":"Sleep"},{"key":"BF02244337_CR18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(84)90483-7","volume":"103","author":"RE Heikkila","year":"1984","unstructured":"Heikkila RE, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241\u2013248","journal-title":"Eur J Pharmacol"},{"key":"BF02244337_CR19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0022-510X(66)90001-3","volume":"3","author":"Y Hishikawa","year":"1966","unstructured":"Hishikawa Y, Ida H, Nakai K, Kaneko Z (1966) Treatment of narcolepsy with imipramine and desmethylimipramine. J Neurol Sci 3:453\u2013459","journal-title":"J Neurol Sci"},{"key":"BF02244337_CR20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1989.tb07161.x","volume":"350","author":"AM Johnson","year":"1989","unstructured":"Johnson AM (1989) An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl 350:14\u201320","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF02244337_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0014-2999(84)90290-5","volume":"98","author":"S Kafi-De St Hilaire","year":"1984","unstructured":"Kafi-De St Hilaire S, Merica H, Gaillard JM (1984) The effects of indalpine \u2014 a selective inhibitor of 5-HTuptake \u2014 on rat paradoxical sleep. Eur J Pharmacol 98:413\u2013418","journal-title":"Eur J Pharmacol"},{"key":"BF02244337_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0031-9384(70)90061-2","volume":"5","author":"AG Karczmar","year":"1970","unstructured":"Karczmar AG, Longo VG, Scotti de Carolis A (1970) A pharmacological model of paradoxical sleep: The role of cholinergic and monoaminergic systems. Physiol Behav 5:175\u2013182.","journal-title":"Physiol Behav"},{"issue":"7","key":"BF02244337_CR23","first-page":"299","volume":"14","author":"MJ Kuhar","year":"1991","unstructured":"Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. TIPS 14[7]:299\u2013302","journal-title":"TIPS"},{"issue":"2","key":"BF02244337_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","volume":"9","author":"N Langdon","year":"1986","unstructured":"Langdon N, Shindler J, Parkes JD, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9[2]:371\u2013373","journal-title":"Sleep"},{"key":"BF02244337_CR25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0006-2952(77)90324-0","volume":"26","author":"G Lefur","year":"1977","unstructured":"Lefur G, Uzan A (1977) Effects of 4-(3-indolylalkyl) piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol 26:497\u2013503","journal-title":"Biochem Pharmacol"},{"key":"BF02244337_CR26","first-page":"429","volume":"10","author":"BA McMillen","year":"1983","unstructured":"McMillen BA (1983) CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. TIPS 10:429\u2013432","journal-title":"TIPS"},{"key":"BF02244337_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF01244452","volume":"83","author":"BA McMillen","year":"1991","unstructured":"McMillen BA, Scott SM, Williams HL (1991) Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotoninergic function. J. Neural Transm [GenSect] 83:55\u201366","journal-title":"J. Neural Transm [GenSect]"},{"issue":"5","key":"BF02244337_CR28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-199243050-00007","volume":"43","author":"D McTavish","year":"1992","unstructured":"McTavish D, Hell RC (1992) Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 43[5]:713\u2013733","journal-title":"Drugs"},{"key":"BF02244337_CR29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1172\/JCI113694","volume":"82","author":"E Mignot","year":"1988","unstructured":"Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC (1988) A role of central alpha 1 adrenoceptors in canine narcolepsy. J Clin Invest 82:885\u2013894","journal-title":"J Clin Invest"},{"key":"BF02244337_CR30","first-page":"90","volume-title":"Genetically determined animal models of neurobehavioral dysfunction","author":"E Mignot","year":"1992","unstructured":"Mignot E, Guilleminault C, Dement WC, Grumet C (1992) Genetically determined animal models of narcolepsy, a disorder of REM sleep. In: Driscoll D (ed) Genetically determined animal models of neurobehavioral dysfunction. Birkhauser Boston Cambridge, pp 90\u2013110"},{"issue":"3","key":"BF02244337_CR31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1523\/JNEUROSCI.13-03-01057.1993","volume":"13","author":"E Mignot","year":"1993","unstructured":"Mignot E, Nishino S, Hunt-Sharp L, Arrigoni J, Siegel JM, Reid MS, Edgar D, Ciaranello RD, Dement WC (1993) Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymtomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 13[3]:1057\u20131064","journal-title":"J Neurosci"},{"key":"BF02244337_CR32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/sleep\/14.3.218","volume":"14","author":"MM Mitler","year":"1991","unstructured":"Mitler MM, Hadjucovic R (1991) Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 14:218\u2013220","journal-title":"Sleep"},{"issue":"1","key":"BF02244337_CR33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/sleep\/9.1.280","volume":"9","author":"J Montplaisir","year":"1986","unstructured":"Montplaisir J, Godbout R (1986) Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 9[1]:280\u2013284","journal-title":"Sleep"},{"key":"BF02244337_CR34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0024-3205(83)90905-0","volume":"32","author":"JM Monti","year":"1983","unstructured":"Monti JM (1983) Minireview: catecholamines and the sleep wake cycle. Life Sci 32:1401\u20131415","journal-title":"Life Sci"},{"issue":"6","key":"BF02244337_CR35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0028-3908(88)90180-3","volume":"27","author":"AN Nicholson","year":"1988","unstructured":"Nicholson AN, Pascoe PA (1988) Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacol, 27[6]:597\u2013602","journal-title":"Neuropharmacol"},{"issue":"10","key":"BF02244337_CR36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0028-3908(86)90153-X","volume":"25","author":"AN Nicholson","year":"1986","unstructured":"Nicholson AN, Pascoe PA (1986) 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25[10]:1079\u20131083","journal-title":"Neuropharmacology"},{"issue":"4","key":"BF02244337_CR37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0028-3908(90)90101-V","volume":"29","author":"AN Nicholson","year":"1990","unstructured":"Nicholson AN, Pascoe PA (1990) Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology 29[4]:411\u2013417","journal-title":"Neuropharmacology"},{"issue":"3","key":"BF02244337_CR38","first-page":"1145","volume":"253","author":"S Nishino","year":"1990","unstructured":"Nishino S, Haak L, Shepperd H, Guilleminault C, Sakai T, Dement WC, Mignot E (1990) Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of REM sleep. J Pharmacol Exp Ther 253[3]:1145\u20131152","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02244337_CR39","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1523\/JNEUROSCI.11-09-02666.1991","volume":"11","author":"S Nishino","year":"1991","unstructured":"Nishino S, Arrigoni J, Valtier D, Miller J, Guilleminault, C, Dement WC, Mignot E (1991) Involvement of dopamine D2-type receptors in the regulation of cataplexy in canine narcolepsy. J Neurosci 11:2666\u20132671","journal-title":"J Neurosci"},{"key":"BF02244337_CR40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/syn.890060113","volume":"6","author":"GG Nomikos","year":"1990","unstructured":"Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106\u2013112","journal-title":"Synapse"},{"issue":"63","key":"BF02244337_CR41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0447.1981.tb00715.x","volume":"290","author":"SO Ogren","year":"1981","unstructured":"Ogren SO, Ross SB, Hall H, Holm AC, Renyi AL (1981) The pharmacology of zimelidine: A 5-HT selective reuptake inhibitor Acta Psychiatr Scand Suppl 290 [63]:127\u2013151","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF02244337_CR42","first-page":"643","volume-title":"Narcolepsy","author":"D Parkes","year":"1976","unstructured":"Parkes D (1976) Amphetamine and alertness. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum New York pp 643\u2013658"},{"key":"BF02244337_CR43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003495-197713060-00001","volume":"13","author":"RM Pinder","year":"1977","unstructured":"Pinder RM, Brodgen RN, Speight TM, Avery GS (1977) Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13:401\u2013421","journal-title":"Drugs"},{"key":"BF02244337_CR44","first-page":"50","volume":"8","author":"V Pliska","year":"1987","unstructured":"Pliska V (1987) Dose-response models: similarity with population growth dynamics. TIPS 8:50\u201352","journal-title":"TIPS"},{"key":"BF02244337_CR45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0028-3908(79)90124-2","volume":"18","author":"P Polc","year":"1979","unstructured":"Polc P, Schneeberger J, Haefely W (1979) Effects of several centrally active drugs on the sleep-wakefulness cycle in cats. Neuropharmacology 18:259\u2013265","journal-title":"Neuropharmacology"},{"issue":"2","key":"BF02244337_CR46","first-page":"213","volume":"20","author":"E Richelson","year":"1984","unstructured":"Richelson E (1984) The newer antidepressants: structures, pharmacokinetics, pharmacodynamics and proposed mechanisms of action. Psychopharmacol Bull 20[2]:213\u2013223","journal-title":"Psychopharmacol Bull"},{"key":"BF02244337_CR47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0014-2999(84)90403-5","volume":"104","author":"E Richelson","year":"1984","unstructured":"Richelson E. Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277\u2013186","journal-title":"Eur J Pharmacol"},{"key":"BF02244337_CR48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-3223(90)90578-P","volume":"28","author":"RJ Ross","year":"1990","unstructured":"Ross RJ, Ball WA, Gresch PJ, Morrison AR (1990) REM sleep suppression by monoamine reuptake blockade: development of tolerance with repeated drug administration. Biol Psychiatry 28:231\u2013239","journal-title":"Biol Psychiatry"},{"key":"BF02244337_CR49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-198937050-00006","volume":"37","author":"MV Rudorfer","year":"1989","unstructured":"Rudorfer MV, Potter WZ (1989) Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the newer versus the older drugs. Drugs 37:713\u2013738","journal-title":"Drugs"},{"issue":"5","key":"BF02244337_CR50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/sleep\/14.5.439","volume":"14","author":"B Saletu","year":"1991","unstructured":"Saletu B, Frey R, Kruptka M, Anderer P, Grunberger J, See WR (1991) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14[5]:439\u2013447","journal-title":"Sleep"},{"key":"BF02244337_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.43.2.171","volume":"43","author":"M Schachter","year":"1980","unstructured":"Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 43:171\u2013174","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02244337_CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0404.1986.tb03518.x","volume":"74","author":"H Schrader","year":"1986","unstructured":"Schrader H, Kayed K, Bendixen Markset B, Treidene HE (1986) The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 74:297\u2013303","journal-title":"Acta Neurol Scand"},{"key":"BF02244337_CR53","first-page":"104","volume-title":"Principles and practice of sleep medicine","author":"JM Siegel","year":"1989","unstructured":"Siegel JM (1989) Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC (eds) Principles and practice of sleep medicine. Saunders, Philadelphia, pp 104\u2013120"},{"issue":"1","key":"BF02244337_CR54","doi-asserted-by":"crossref","first-page":"001","DOI":"10.1002\/j.1875-9114.1987.tb03496.x","volume":"7","author":"RW Sommi","year":"1987","unstructured":"Sommi RW, Crismon ML, Bowden CL (1987) Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 7 [1]:001\u2013015","journal-title":"Pharmacotherapy"},{"key":"BF02244337_CR55","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.2042-7158.1977.tb11460.x","volume":"29","author":"FE Soroko","year":"1977","unstructured":"Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH (1977) Bupropion hydrochloride [(\u00b1) alpha-t-butylamino-3-chloropiophenone HCl]: a novel antidepressant agent. J Pharm Pharmacol 29:767\u2013770","journal-title":"J Pharm Pharmacol"},{"key":"BF02244337_CR56","volume-title":"Brainstem control of wakefulness and sleep","year":"1990","unstructured":"Steriade M, McCarley R (eds) (1990) Brainstem control of wakefulness and sleep. Plenum, New York"},{"key":"BF02244337_CR57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(90)94155-Q","volume":"191","author":"SM Tejani-Butt","year":"1990","unstructured":"Tejani-Butt SM, Brunswick DJ, Frazer A (1990) [3H]-Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191:239\u2013243","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"BF02244337_CR58","first-page":"7","volume":"(suppl) 53","author":"IA Tulloch","year":"1992","unstructured":"Tulloch IA, Johnson AM (1992) The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry (suppl) 53[2]:7\u201312","journal-title":"J Clin Psychiatry"},{"key":"BF02244337_CR59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.2042-7158.1982.tb04737.x","volume":"34","author":"PC Waldmeier","year":"1982","unstructured":"Waldmeier PC (1982) Effects of antidepressant drugs on dopamine uptake and metabolism. J Pharm Pharmacol 34:391\u2013394","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"BF02244337_CR60","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0006-2952(83)90284-8","volume":"32","author":"DT Wong","year":"1983","unstructured":"Wong DT, Bymaster FP, Reid LR, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32[7]:1287\u20131293","journal-title":"Biochem Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02244337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02244337\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02244337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:32:01Z","timestamp":1557862321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02244337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,11]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,11]]}},"alternative-id":["BF02244337"],"URL":"https:\/\/doi.org\/10.1007\/bf02244337","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,11]]}}}